Eli Lilly, Regeneron Report Positive Phase III COVID-19 Antibody Results

Eli Lilly’s bamlanivimab-etesevimab combination and Regeneron Pharmaceuticals’ REGEN-COV outperformed placebo in late-stage clinical trials, according to the companies.

The post Eli Lilly, Regeneron Report Positive Phase III COVID-19 Antibody Results appeared first on GEN – Genetic Engineering and Biotechnology News.

Published on Wed, 27 Jan 2021 13:30:27 +0000 and sponsored by nintex replace text in collection